Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2024.02.007

Abstract

Abstract:

Patients with chronic kidney disease, especially end-stage renal disease, who are receiving renal replacement therapy, are at great risk in the epidemic of COVID-19. Studies have shown that the existing COVID-19 vaccines are safe for patients with chronic kidney disease, and the whole course of vaccination can produce specific antibodies in most patients with chronic kidney disease. However, the humoral response and efficacy of the vaccines in patients with chronic kidney disease were significantly weaker than in healthy people. Increase of the number of vaccinations and use of combined vaccinations may have potential value in improving the protective efficacy of the vaccines in patients with chronic kidney disease, but the relevant vaccination strategies still need to be further studied. This paper reviewed the research progress on the feasibility, safety, efficacy, and targeted vaccination strategies of the SARS-CoV-2 vaccination for patients with chronic kidney disease.

Key words: Chronic kidney disease, COVID-19, SARS-CoV-2, Vaccination

Jinyi Zhang, Yuehong Li. Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 97-100.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2024.02.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2024/V13/I02/97

References 43

[1]	Russo AG, Decarli A, Valsecchi MG. Strategy to identify priority groups for COVID-19 vaccination: a population based cohort study [J]. Vaccine, 2021, 39(18): 2517-2525.
[2]	Glenn DA, Hegde A, Kotzen E, et al. Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease [J]. Kidney Int Rep, 2021, 6(5): 1407-1410.
[3]	Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation [J]. Am J Kidney Dis, 2020, 75(3): 417-425.
[4]	Longlune N, Nogier MB, Miedouge M, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients [J]. Nephrol Dial Transplant, 2021, 36(9): 1704-1709.
[5]	Park JS, Minn D, Hong S, et al. Immunogenicity of COVID-19 vaccination in patients with end-stage renal disease undergoing maintenance hemodialysis: the efficacy of a mix-and-match strategy [J]. J Korean Med Sci, 2022, 37(23): e180.
[6]	Attias P, Sakhi H, Rieu P, et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients [J]. Kidney Int, 2021, 99(6): 1490-1492.
[7]	Grupper A, Sharon N, Finn T, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis [J]. Clin J Am Soc Nephrol, 2021, 16(7): 1037-1042.
[8]	Speer C, Goth D, Benning L, et al. Early humoral responses of hemodialysis patients after COVID-19 vaccination with BNT162b2 [J]. Clin J Am Soc Nephrol, 2021, 16(7): 1073-1082.
[9]	Torreggiani M, Blanchi S, Fois A, et al. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won [J]. Kidney Int, 2021, 99(6): 1494-1496.
[10]	Kolb T, Fischer S, Muller L, et al. Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients [J]. Kidney360, 2021, 2(9): 1491-1498.
[11]	Goupil R, Benlarbi M, Beaubien-Souligny W, et al. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis [J]. CMAJ, 2021, 193(22): E793-E800.
[12]	Yau K, Abe KT, Naimark D, et al. Evaluation of the SARS-CoV-2 antibody response to the BNT162b2 vaccine in patients undergoing hemodialysis [J]. JAMA Netw Open, 2021, 4(9): e2123622.
[13]	Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant [J]. Transplantation, 2022, 106(4): 821-834.
[14]	Billany RE, Selvaskandan H, Adenwalla SF, et al. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms [J]. Kidney Int, 2021, 99(6): 1492-1494.
[15]	Brunelli SM, Sibbel S, Karpinski S, et al. Comparative effectiveness of mRNA-based BNT162b2 vaccine versus adenovirus vector-based Ad26.COV2.S vaccine for the prevention of COVID-19 among dialysis patients [J]. J Am Soc Nephrol, 2022, 33(4): 688-697.
[16]	Zhang YM, Liu XZ, Lin MM, et al. Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients [J]. J Infect, 2022, 85(2): 174-211.
[17]	Li H, Cai D, Jiang D, et al. Risk of waning humoral responses after inactivated or subunit recombinant SARS-CoV-2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China [J]. J Med Virol, 2023, 95(1): e28434.
[18]	Sibbel S, Mckeon K, Luo J, et al. Real-world effectiveness and immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients on hemodialysis [J]. J Am Soc Nephrol, 2022, 33(1): 49-57.
[19]	Oliver MJ, Thomas D, Balamchi S, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes in the maintenance dialysis population in ontario, canada [J]. J Am Soc Nephrol, 2022, 33(4): 839-849.
[20]	Ashby DR, Caplin B, Corbett RW, et al. Severity of COVID-19 after vaccination among hemodialysis patients: an observational cohort study [J]. Clin J Am Soc Nephrol, 2022, 17(6): 843-850.
[21]	Torres R, Toro L, Sanhueza ME, et al. Clinical efficacy of SARS-CoV-2 vaccination in hemodialysis patients [J]. Kidney Int Rep, 2022, 7(10): 2176-2185.
[22]	Karoui K, Hourmant M, Ayav C, et al. Vaccination and COVID-19 dynamics in dialysis patients [J]. Clin J Am Soc Nephrol, 2022, 17(3): 395-402.
[23]	Hernandez-Porto M, Garcia S, Delgado T, et al. Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis [J]. Int J Infect Dis, 2022, 122: 327-331.
[24]	Attias P, Azzaoui I, Karoui K, et al. Immune responses after a third dose of mRNA vaccine differ in virus-naive versus SARS-CoV-2- recovered dialysis patients [J]. Clin J Am Soc Nephrol, 2022, 17(7): 1008-1016.
[25]	Kanai D, Wakui H, Haze T, et al. Improved immune response to the third COVID-19 mRNA vaccine dose in hemodialysis patients [J]. Kidney Int Rep, 2022, 7(12): 2718-2721.
[26]	Garcia P, Han J, Montez-Rath ME, et al. SARS-CoV-2 booster vaccine response among patients receiving dialysis [J]. Clin J Am Soc Nephrol, 2022, 17(7): 1036-1038.
[27]	Montez-Rath ME, Garcia P, Han J, et al. SARS-CoV-2 infection during the omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses [J]. J Am Soc Nephrol, 2022, 33(10): 1832-1839.
[28]	Einbinder Y, Perl J, Nacasch N, et al. Humoral response and SARS-CoV-2 infection risk following the third and fourth doses of the BNT162b2 vaccine in dialysis patients [J]. Am J Nephrol, 2022, 53(7): 586-590.
[29]	Housset P, Kubab S, Hanafi L, et al. Humoral response after a fourth "booster" dose of a coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients [J]. Kidney Int, 2022, 101(6): 1289-1290.
[30]	Anft M, Blazquez-Navarro A, Frahnert M, et al. Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses [J]. Kidney Int, 2022, 102(1): 207-208.
[31]	Ovcar E, Patyna S, Kohmer N, et al. Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients [J]. Clin Kidney J, 2022, 15(12): 2346-2348.
[32]	Kim DK, Jung SW, Moon JY, et al. Severe acute respiratory syndrome coronavirus 2 antibody response after heterologous immunizations with ChAdOx1/BNT162b2 in end-stage renal disease patients on hemodialysis [J]. Front Immunol, 2022, 13: 894700.
[33]	Mrak D, Sieghart D, Simader E, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial [J]. Nat Commun, 2022, 13(1): 5362.
[34]	Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine [J]. N Engl J Med, 2021, 384(5): 403-416.
[35]	张金铭，张治伦. 终末期肾病血液透析患者接种新冠病毒灭活疫苗的临床研究[J]. 中国社区医师，2022, 38(35): 57-59.
[36]	于海波，王立华，王喆，等. 维持性血液透析患者接种新型冠状病毒肺炎疫苗的安全性及影响因素[J]. 中华肾脏病杂志，2023, 39(2): 112-118.
[37]	Tan HZ, Tan RY, Choo JC, et al. Is COVID-19 vaccination unmasking glomerulonephritis? [J]. Kidney Int, 2021, 100(2): 469-471.
[38]	D′agati VD, Kudose S, Bomback AS, et al. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine [J]. Kidney Int, 2021, 100(2): 461-465.
[39]	Gondor G, Ksiazek SH, Regele H, et al. Development of crescentic membranoproliferative glomerulonephritis after COVID-19 vaccination [J]. Clin Kidney J, 2022, 15(12): 2340-2342.
[40]	Kervella D, Jacquemont L, Chapelet-Debout A, et al. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine [J]. Kidney Int, 2021, 100(2): 457-458.
[41]	Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy [J]. Kidney Int, 2021, 99(6): 1487.
[42]	Komaba H, Wada T, Fukagawa M. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine [J]. Am J Kidney Dis, 2021, 78(3): 469-470.
[43]	Aydin MF, Yildiz A, Oruc A, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination [J]. Kidney Int, 2021, 100(2): 464-465.

Please choose a citation manager

Content to export